Detalhe da pesquisa
1.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310904
2.
Exploration of baseline patient-reported side effect bother from cancer therapy.
Clin Trials
; 17(3): 332-337, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32153216
3.
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist
; 24(4): 563-569, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30541754
4.
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Liver Int
; 38(6): 976-987, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603856
5.
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Oncologist
; 21(5): 634-42, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26984449
6.
Bone-targeting agents in prostate cancer.
Cancer Metastasis Rev
; 33(2-3): 619-28, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24398856
7.
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Prostate
; 75(15): 1814-20, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26306637
8.
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Prostate
; 74(13): 1278-85, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25053178
9.
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis.
J Natl Cancer Inst
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486364
10.
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res
; 30(10): 2011-2016, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441576
11.
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
J Clin Oncol
; 42(14): 1687-1698, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38484203
12.
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Clin Cancer Res
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416426
13.
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 42(15): 1851-1860, 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452327
14.
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 29(9): 1651-1657, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469000
15.
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084090
16.
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Clin Cancer Res
; 28(6): 1058-1071, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711631
17.
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 26(18): 4717-4722, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32284318
18.
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies.
Clin Cancer Res
; 26(24): 6406-6411, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732222
19.
Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.
Ann Hematol
; 93(7): 1245-6, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24232305
20.
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
Oncology (Williston Park)
; 28(10): 880, 882, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25323614